238 related articles for article (PubMed ID: 29596062)
21. Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.
Jahan N; Talat H; Curry WT
Neuro Oncol; 2018 Jan; 20(1):44-54. PubMed ID: 29016879
[TBL] [Abstract][Full Text] [Related]
22. Tumor vaccine based on cell surface expression of DcR3/TR6.
Shi G; Mao J; Yu G; Zhang J; Wu J
J Immunol; 2005 Apr; 174(8):4727-35. PubMed ID: 15814697
[TBL] [Abstract][Full Text] [Related]
23. Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.
Kumai T; Lee S; Cho HI; Sultan H; Kobayashi H; Harabuchi Y; Celis E
Cancer Immunol Res; 2017 Jan; 5(1):72-83. PubMed ID: 27941004
[TBL] [Abstract][Full Text] [Related]
24. Prevention of spontaneous tumor development in a ret transgenic mouse model by ret peptide vaccination with indoleamine 2,3-dioxygenase inhibitor 1-methyl tryptophan.
Zeng J; Cai S; Yi Y; He Y; Wang Z; Jiang G; Li X; Du J
Cancer Res; 2009 May; 69(9):3963-70. PubMed ID: 19383920
[TBL] [Abstract][Full Text] [Related]
25. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
Davila E; Celis E
J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
[TBL] [Abstract][Full Text] [Related]
26. CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts.
den Boer AT; van Mierlo GJ; Fransen MF; Melief CJ; Offringa R; Toes RE
Cancer Res; 2005 Aug; 65(15):6984-9. PubMed ID: 16061684
[TBL] [Abstract][Full Text] [Related]
27. Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies.
Gray JC; French RR; James S; Al-Shamkhani A; Johnson PW; Glennie MJ
Eur J Immunol; 2008 Sep; 38(9):2499-511. PubMed ID: 18792403
[TBL] [Abstract][Full Text] [Related]
28. Cancer immunotherapy: moving forward with peptide T cell vaccines.
Kumai T; Fan A; Harabuchi Y; Celis E
Curr Opin Immunol; 2017 Aug; 47():57-63. PubMed ID: 28734176
[TBL] [Abstract][Full Text] [Related]
29. Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice.
Iwama T; Uchida T; Sawada Y; Tsuchiya N; Sugai S; Fujinami N; Shimomura M; Yoshikawa T; Zhang R; Uemura Y; Nakatsura T
Biochem Biophys Res Commun; 2016 Jan; 469(1):138-143. PubMed ID: 26616051
[TBL] [Abstract][Full Text] [Related]
30. In vivo scintigraphic imaging of antitumor effects by combined radioiodine therapy and human sodium iodide symporter gene immunotherapy.
Choi Y; Jeon YH; Paik JH; Ko J; Choi DH; Chung JK; Kim CW
Mol Imaging; 2010 Jun; 9(3):141-52. PubMed ID: 20487680
[TBL] [Abstract][Full Text] [Related]
31. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.
Fotin-Mleczek M; Duchardt KM; Lorenz C; Pfeiffer R; Ojkić-Zrna S; Probst J; Kallen KJ
J Immunother; 2011 Jan; 34(1):1-15. PubMed ID: 21150709
[TBL] [Abstract][Full Text] [Related]
32. Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells.
Koido S; Tanaka Y; Tajiri H; Gong J
Vaccine; 2007 Mar; 25(14):2610-9. PubMed ID: 17239504
[TBL] [Abstract][Full Text] [Related]
33. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
34. STAT3-blocked whole-cell hepatoma vaccine induces cellular and humoral immune response against HCC.
Han Q; Wang Y; Pang M; Zhang J
J Exp Clin Cancer Res; 2017 Nov; 36(1):156. PubMed ID: 29115974
[TBL] [Abstract][Full Text] [Related]
35. Whole-body PET Imaging of T-cell Response to Glioblastoma.
Nobashi TW; Mayer AT; Xiao Z; Chan CT; Chaney AM; James ML; Gambhir SS
Clin Cancer Res; 2021 Dec; 27(23):6445-6456. PubMed ID: 34548318
[TBL] [Abstract][Full Text] [Related]
36. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
37. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.
Gatza E; Okada CY
J Immunol; 2002 Nov; 169(9):5227-35. PubMed ID: 12391241
[TBL] [Abstract][Full Text] [Related]
38. DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies.
Le Pogam C; Patel S; Gorombei P; Guerenne L; Krief P; Omidvar N; Tekin N; Bernasconi E; Sicre F; Schlageter MH; Chopin M; Noguera ME; West R; Abu A; Mathews V; Pla M; Fenaux P; Chomienne C; Padua RA
Oncotarget; 2015 Oct; 6(32):32494-508. PubMed ID: 26378812
[TBL] [Abstract][Full Text] [Related]
39. Immunotargeting and eradication of orthotopic melanoma using a chemokine-enhanced DNA vaccine.
Igoucheva O; Grazzini M; Pidich A; Kemp DM; Larijani M; Farber M; Lorton J; Rodeck U; Alexeev V
Gene Ther; 2013 Sep; 20(9):939-48. PubMed ID: 23552473
[TBL] [Abstract][Full Text] [Related]
40. Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study.
Weinberg AD; Thalhofer C; Morris N; Walker JM; Seiss D; Wong S; Axthelm MK; Picker LJ; Urba WJ
J Immunother; 2006; 29(6):575-85. PubMed ID: 17063120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]